PhillipCapital analyst Paul Chew has maintained a “buy” rating on Hyphens Pharma International with an unchanged target price of 34.5 cents. 

For the 9MFY2021 ended September, Hyphens Pharma reported PATMI of $1.09 million, 28.8% higher y-o-y. The figure stood above Chew’s expectations at 88% of his FY2021 forecast.

To this end, Chew has raised his PATMI estimates for the FY2021 by 6% due to higher margins as the group’s mix of proprietary brands increases as well.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook